GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to ...